Treatment and prevention of aortic regurgitation after transcatheter aortic valve implantation

Kentaro Hayashida, Thierry Lefèvre

研究成果: Review article査読

3 被引用数 (Scopus)

抄録

Significant aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) has been shown to be associated with worse mid-term outcome. The two-year follow-up results of the PARTNER US trial showed that not only ≥3/4 AR grade, but also grade 2 had a significant impact on mortality. Thus, prevention and treatment of significant AR after TAVI is of great importance. Usually, AR after TAVI consists mostly of paravalvular leak and significant central AR is uncommon. Here we describe measures to decrease the risk of AR after TAVI which are currently available.

本文言語English
ページ(範囲)Q34-Q40
ジャーナルEuroIntervention
8
DOI
出版ステータスPublished - 2012 1 1

ASJC Scopus subject areas

  • 循環器および心血管医学

フィンガープリント

「Treatment and prevention of aortic regurgitation after transcatheter aortic valve implantation」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル